Differential expression of fibronectin leucine rich transmembrane protein 2 in cancers of the breast.
Breast cancer affects women at relatively high frequency1. We mined published microarray datasets2,3 to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding fibronectin leucine rich transmembrane protein 2, FLRT2, when comparing primary tumors of the breast to the tissue of origin, the normal breast. FLRT2 mRNA was present at significantly lower quantities in tumors of the breast as compared to normal breast tissue. Analysis of human survival data revealed that expression of FLRT2 in primary tumors of the breast was correlated with overall survival in patients with basal and luminal A subtype breast cancer, but not in luminal B or HER2+ breast cancer, demonstrating a relationship between primary tumor expression of a differentially expressed gene and patient survival outcomes influenced by molecular subtype. FLRT2 may be of relevance to initiation, maintenance or progression of cancers of the female breast.